These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36674961)

  • 1. Assessment of Neurotoxic Effects of Oxycodone and Naloxone in SH-SY5Y Cell Line.
    Lima LS; da Costa NS; Galiciolli MEA; Pereira ME; Almeida W; Margarete Cestari M; Nogara PA; Irioda AC; Oliveira CS
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid-Induced Bowel Dysfunction in Patients Undergoing Spine Surgery: Comparison of Oxycodone and Oxycodone-Naloxone Treatment.
    Kokki M; Kuronen M; Naaranlahti T; Nyyssönen T; Pikkarainen I; Savolainen S; Kokki H
    Adv Ther; 2017 Jan; 34(1):236-251. PubMed ID: 27921252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.
    Simpson K; Leyendecker P; Hopp M; Müller-Lissner S; Löwenstein O; De Andrés J; Troy Ferrarons J; Bosse B; Krain B; Nichols T; Kremers W; Reimer K
    Curr Med Res Opin; 2008 Dec; 24(12):3503-12. PubMed ID: 19032132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in managing severe chronic pain: role of oxycodone-naloxone extended release.
    Fanelli G; Fanelli A
    Drug Des Devel Ther; 2015; 9():3811-6. PubMed ID: 26229442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.
    Haeseler G; Schaefers D; Prison N; Ahrens J; Liu X; Karch A
    BMC Anesthesiol; 2017 Jul; 17(1):91. PubMed ID: 28693439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analgesic Efficacy and Safety of Prolonged-Release Oxycodone/Naloxone in Korean Patients with Chronic Pain from Spinal Disorders.
    Hwang CJ; Chung SS; Lee KY; Lee JH; Moon SH; Kim JH; Cho KJ; Ahn JS; Kim DS; Park YS; Park HJ
    Clin Orthop Surg; 2018 Mar; 10(1):33-40. PubMed ID: 29564045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of prolonged-released oxycodone/naloxone in postoperative pain management after total knee replacement: a nonrandomized prospective trial.
    Oppermann J; Bredow J; Spies CK; Lemken J; Unglaub F; Boese CK; Dargel J; Eysel P; Zöllner J
    J Clin Anesth; 2016 Sep; 33():491-7. PubMed ID: 27555214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe, chronic cancer pain: Challenges in the context of hepatic impairment.
    Le BH; Aggarwal G; Douglas C; Green M; Nicoll A; Ahmedzai S
    Asia Pac J Clin Oncol; 2022 Feb; 18(1):13-18. PubMed ID: 33660420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.
    Burness CB; Keating GM
    Drugs; 2014 Mar; 74(3):353-75. PubMed ID: 24452879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of oxycodone prolonged-release vs. oxycodone + naloxone prolonged-release after laparoscopic hysterectomy.
    Comelon M; Wisloeff-Aase K; Raeder J; Draegni T; Undersrud H; Qvigstad E; Bjerkelund CE; Lenz H
    Acta Anaesthesiol Scand; 2013 Apr; 57(4):509-17. PubMed ID: 23301686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
    Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
    J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice.
    Kuusniemi K; Zöllner J; Sjövall S; Huhtala J; Karjalainen P; Kokki M; Lemken J; Oppermann J; Kokki H
    J Int Med Res; 2012; 40(5):1775-93. PubMed ID: 23206459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxycodone-Naloxone Combination Hinders Opioid Consumption in Osteoarthritic Chronic Low Back Pain: A Retrospective Study with Two Years of Follow-Up.
    Polati E; Nizzero M; Rama J; Martini A; Gottin L; Donadello K; Del Balzo G; Varrassi G; Marinangeli F; Vittori A; Secchettin E; Schweiger V
    Int J Environ Res Public Health; 2022 Oct; 19(20):. PubMed ID: 36293936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of oxycodone/naloxone in the management of patients with pain and opioid-induced constipation.
    Leppert W; Zajaczkowska R; Wordliczek J
    Expert Opin Pharmacother; 2019 Apr; 20(5):511-522. PubMed ID: 30625013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
    Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
    Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
    Ueberall MA; Mueller-Schwefe GH
    Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study.
    Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
    Eur J Pain; 2017 Oct; 21(9):1485-1494. PubMed ID: 28474460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of oxycodone and oxycodone/naloxone in cancer pain management.
    Leppert W
    Pharmacol Rep; 2010; 62(4):578-91. PubMed ID: 20884999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.
    Sandner-Kiesling A; Leyendecker P; Hopp M; Tarau L; Lejcko J; Meissner W; Sevcik P; Hakl M; Hrib R; Uhl R; Dürr H; Reimer K
    Int J Clin Pract; 2010 May; 64(6):763-74. PubMed ID: 20370845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.